



Using SGLT2- inhibitors: a new oral medication, for feline diabetes



May 29, 2024, at 7 p.m. (EDT)

4:00

BC (PDT)

5:00

AB/SK (MDT)

6:00

MB (CDT)

7:00

ON/QC (EDT)

8:00

PEI/NB/NS (ADT)

8:30

NL (NDT)

During this webcast, **Dr. Ellen Behrend** will discuss sodium-glucose co-transporter-2 inhibitors (SGLT2i) for the treatment of feline diabetes mellitus. She will explore their mechanism of action, evaluating their efficacy and potential adverse effects within the context of feline care. Additionally, she will provide invaluable insights on patient selection, optimal usage, and essential monitoring protocols.

Join us to enhance your understanding of this latest advancement
in feline diabetes management.



Ellen N. Behrend

VMD, PhD, Dipl. ACVIM (Small Animal Internal Medicine)

Dr. Behrend received her VMD degree from the University of Pennsylvania in 1988 and her PhD from Auburn University in 2001. She has authored numerous scientific publications, including journal articles, book chapters, and abstracts, and served as a section editor for several textbooks. She has provided hundreds of continuing education lectures at national and international conferences. She currently is a consultant for the Veterinary Information Network. Dr. Behrend is the Joezy Griffin Professor Emerita in the Department of Clinical Sciences at Auburn University and has won the Zoetis Distinguished Teaching Award three times.

Sign up now for this live webcast at communiVET.com/webcast/SGLT2inhibitors

Click here to sign up NOW!

Presented by



Powered by

